Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Olaptesed Pegol

Generic Name: Olaptesed Pegol

Drug Type: Small Molecule

CAS Number: 1390628-22-4

Unique Ingredient Identifier: MTM792B442

Overview

Olaptesed Pegol has been investigated for the treatment of Hematopoietic Stem Cell Transplantation.

Background

Olaptesed Pegol has been investigated for the treatment of Hematopoietic Stem Cell Transplantation.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Phase 2

Not yet recruiting

Posted: 2021/05/25

Sponsor:

TME Pharma AG

ID:NCT04901741

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Phase 1

Active, not recruiting

Posted: 2019/10/10

Sponsor:

TME Pharma AG

ID:NCT04121455

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Phase 2

Completed

Posted: 2012/01/30

Sponsor:

TME Pharma AG

ID:NCT01521533

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Posted: 2011/12/07

Sponsor:

TME Pharma AG

ID:NCT01486797

NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers

Phase 1

Completed

Posted: 2010/09/03

Sponsor:

TME Pharma AG

ID:NCT01194934

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

2 months ago

The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.

TME Pharma Partners with aimed analytics to Advance AI-Driven Cancer Drug Development

4 months ago

TME Pharma, a clinical-stage oncology company, has established a strategic collaboration with aimed analytics to enhance drug discovery and optimization through artificial intelligence technologies.

TME Pharma's NOX-A12 Shows Significant Survival Benefit in Glioblastoma Trial

7 months ago

TME Pharma's NOX-A12, combined with bevacizumab and radiotherapy, demonstrated a statistically significant survival benefit in glioblastoma patients compared to standard of care.

Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment

3 years ago

Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy